Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(559)
•••
Post by chrispion Jun 16, 2022 8:48am
139 Views
Post# 34760700

Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

Bioasis Acquires Phase 2 Ready Rare Orphan EGF AssetsThis is fantastic news! :) https://www.globenewswire.com/news-release/2022/06/16/2463857/0/en/Bioasis-Acquires-Phase-2-Ready-Rare-Orphan-EGF-Assets.html

Finally people can't say "you aren't in the clinic (human dosing) with xB3" anymore.
It might not happen today (with the overall depressed market given the Fed's interest rate decision yesterday) but this opens investment in Bioasis to a new set of investors on both sides of the border.

Just the start of good things till the end of the year imo.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities